Regulatory News
Tuesday, April 19, 2016
UPDATE 1-Bristol-Myers' Opdivo extends survival in head and neck cancer -study
April 19 (Reuters) - Bristol-Myers Squibb's cancer
immunotherapy drug, Opdivo, helped advanced head and neck cancer
patients with a dismal prognosis live longer than other standard
treatments,...
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment